US OptionsDetailed Quotes
SMMT250425C24000
- 6.90
- +2.70+64.29%
15min DelayClose Apr 23 16:00 ET
7.50High6.00Low
6.00Open4.20Pre Close6 Volume38 Open Interest24.00Strike Price4.11KTurnover0.00%IV-7.01%PremiumApr 25, 2025Expiry Date9.23Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.82Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
oh well.
Summit Therapeutics Inc - Harmoni-6 Phase III Trial Meets Primary Endpoint of Pfs
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
Subscribe to Premium: LINK
$CoreWeave (CRWV.US)$ $Summit Therapeutics (SMMT.US)$ $Carvana (CVNA.US)$ $Aurora Innovation (AUR.US)$ $Coherent (COHR.US)$ $Tesla (TSLA.US)$ $NVIDIA (NVDA.US)$ $Newsmax (NMAX.US)$ $Palantir (PLTR.US)$
Billion-Dollar Oncology Expert Robert LaCaze to Drive Summit Therapeutics Cancer Drug Launch
Can This Summit-Pfizer Cancer Drug Combo Revolutionize Solid Tumor Treatment?
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded fell 0.50%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0.08%, and the $Nasdaq Composite Index (.IXIC.US)$...
Can This New Summit-Pfizer Cancer Drug Combo Transform Solid Tumor Treatment?
No comment yet